Tamoxifen treatment of estrogen receptor (ER)-positive breast cancer reduces mortality by 31%. However, 13 over half of advanced ER-positive breast cancers are intrinsically resistant to tamoxifen and about 40% 14 will acquire the resistance during the treatment. In order to explore mechanisms underlying endocrine 15 therapy resistance in breast cancer and to identify new therapeutic opportunities, we created tamoxifen-16 resistant breast cancer cell lines that represent the luminal A or the luminal B. Gene expression patterns 17 revealed by RNA-sequencing in seven tamoxifen-resistant variants were compared with their isogenic 18 parental cells. We show that tamoxifen resistance cannot simply be explained by altered expression of 19 individual genes, common mechanism across all resistant variants, or the appearance of new fusion genes. 20
Introduction 29
Approximately two thirds of breast cancers are estrogen receptor (ER) positive. As the receptor stimulates 30 proliferation of mammary epithelial cells, it is also an important target in anti-hormonal cancer therapy. 31 One of the most prescribed ER antagonists for first line therapy is tamoxifen (Chang 2012; Harper and 32 Walpole 1967) that has helped millions of women since its discovery 50 years ago (Jordan 2003) . However, 33
de novo or acquired drug resistance towards tamoxifen is a notable problem and the later affects 34 approximately 40% of patients receiving tamoxifen (Ring and Dowsett 2004 In addition to its intended anti-cancer effects, tamoxifen is known to have both direct and indirect effects 39 on the cellular lipid metabolism. It has been shown to reduce blood cholesterol levels (Caleffi et al. 1988 ) 40 and to be protective against cardiovascular diseases (Rutqvist and Mattsson 1993; McDonald et al. 1995) . 41 However, approximately 43% of the patients treated with tamoxifen develop hepatic steatosis, including 42 the accumulation of neutral lipids to lipid droplets in hepatic cells (Nishino et al. 2003) . Tamoxifen can 43 regulate the lipid balance e.g by binding to the microsomal antiestrogen binding sites (AEBS), which are 44 associated with cholesterol metabolism (Kedjouar et al. 2004 ; de Medina et al. 2011 ). This mechanism has 45 been linked to control cell growth, differentiation and apoptosis in the presence of reactive oxygen species 46 (ROS) and has been established as another mode by which tamoxifen induces cytotoxicity (Payré et al. 47 2008; Bekele et al. 2016) . 48
On the other hand, reprogrammed metabolism is one hallmark of cancer cells (Pavlova and Thompson 49 2016) and has recently been suggested as a new mode of drug resistance in cancer therapy ( cholesterol-lowering medication during their adjuvant endocrine therapy (Borgquist et al. 2017) . 56
In the present study, we have delineated mechanisms underlying tamoxifen resistance by extending our 57 drug screening and exome sequencing analyses on tamoxifen-resistant cell lines (Kangaspeska et al. 2016 ) 58 by performing RNA-sequencing on the tamoxifen-resistant and their isogenic, tamoxifen-sensitive 59 parental cell lines, and searched for genes and pathways that may be involved in the acquired resistance. 60
Differential gene expression and pathway analysis confirmed that endocrine resistance is not triggered by 61 one common mechanism but involves several functional pathways, depending on the cell type 62 (Kangaspeska et al. 2016) . Through the integration with public data (McBryan et al. 2015) , the usefulness 63 of our breast cancer cell line model was assessed and the relevance of the identified transcriptomic 64 alterations verified in this patient cohort. By focusing on the isogenic T-47D cell variants, we showed that 65 genes in the cholesterol pathway were differentially expressed between tamoxifen-sensitive and 66 tamoxifen-resistant cells. These results were supported by a striking accumulation of lysosomal 67 cholesterol upon tamoxifen treatment, increased neutral lipid amounts after the development of 68 resistance. Markedly, tamoxifen treated cells were also found to be less prone to lysosomal membrane 69 permeabilization, suggesting that altered lysosomal integrity may confer resistance to tamoxifen. Finally, 70
using high-content phenotypic drug sensitivity profiling of 33 drugs targeting lipid metabolism as well as 71
inducing lysosomal membrane leakage, we identified drug candidates for overwriting the tamoxifen 72 resistance and potentially being beneficial for breast cancer patients unresponsive to tamoxifen. 73
74
Methods 75
Cell culture 76
The development, characterization and culturing of the tamoxifen-resistant and their isogenic parental 77 cell lines has been published previously (Kangaspeska et al. 2016 Parental and resistant T-47D cells were plated on 6-well plates and grown in their default media +/-1 µM 122 4-OH-tamoxifen for 72 h in triplicates. Cells were scraped in 0.2 N NaOH for lipids extraction as previously 123
described (Bligh and Dyer 1959) . Cell lysates were also examined for protein amount. Free cholesterol, 124 cholesterol esters and triglycerides were resolved on TLC plates using hexane/diethyl ether/acetic acid 125 (80∶20∶1) as the mobile phase prior to the visualization of lipids by charring. The lipid bands were 126 quantified by ImageJ (Schneider, Rasband, and Eliceiri 2012) from scanned plates and the lipid amounts 127
were determined based on the standard curves for triglycerides, cholesterol esters and free cholesterol. 128
Immunofluorescence staining and Western blotting 129
Parental and resistant T-47D cells were seeded on coverslips and grown in the default media +/-tamoxifen 130 for 72 h. Cells were fixed with 4 % paraformaldehyde for 20 minutes at room temperature, and 131 permeabilized with 0.3 % Triton X-100 for 5 minutes, followed by 30 min blocking with 3 % BSA-PBS at 132 37 °C. The primary and secondary antibodies were diluted in 1 % BSA-PBS and consecutively incubated for 133 60 and 30 min at 37 °C. For detection of free cholesterol, cells were stained with 0.05 % filipin (Sigma) in 134 10% FBS-PBS blocking solution for 30 minutes at 37 °C. Antibodies were prepared in 5 % FBS-PBS and 135 incubated as described above. Nuclei were stained with DRAQ5 (Biostatus). For detecting lipid droplets, 136
LipidTOXGreen neutral lipid stain (ThermoFisher Scientific) was diluted 1:200 in PBS to stain freshly fixed 137 coverslips following the manufactures protocol and detecting the nuclei with Hoechst. Stained coverslips 138
were mounted with Prolong Gold anti-fade reagent (Invitrogen) and imaged with a Nikon 90i microscope 139 (Niko n). Fo r West ern blo t t ing, c ells wer e gro wn o n 1 0 c m dishes, and lysed in L aemml i buffer. 140
Immunoblotting was performed as previously described (Leivonen et al. 2009 ) using the Odyssey Blocking 141
Buffer (Licor) for blocking and the antibody dilutions. The protein intensity was quantified with ImageJ 142 and normalized to β-actin/-tubulin, respectively. Information about the antibodies and their dilution used 143
for immunofluorescence as well as Western blotting is available at Additional File 1. 144 145
Lysosomal membrane permeabilization (LMP) assay 146
In order to measure the integrity of lysosomal membranes, we performed the detection of damaged 147
lysosomes by galectin-1 and -3 translocation according to the previously published protocol (Aits, Jäättelä, 148
and Nylandsted 2015). We first established that galectin-3 was in our cell lines a more reliable marker to 149 detect its translocalization to the lysosomes compared to galectin-1. We then seeded containing Opera Phenix HCS system (PerkinElmer) in a widefield mode with the 40x water immersion 156 objective (NA 1.1). Exposure time and laser power were kept constant for each individual staining across 157 different cell lines and conditions. We utilized the Columbus Image Data Storage and Analysis System 158 (PerkinElmer) to analyze the multi-channel images. First, the images were preprocessed to correct non-159 uniform illumination. Next, individual nuclei were segmented from the Hoechst channel. The minimum 160 area of a nucleus was set to 30 µm² to remove the detection of debris in the image background. Starting 161 from the detected nuclei, the segmented regions were propagated to cover cell cytoplasm stained with 162
ceruloplasmin. The cells that touched the image border were discarded. Finally, spot detection was used 163
to segment galectin-3 stained spots. The maximum radius of the spots was set to 1 µm. We defined cells 164
with more than 1 spot as galectin-3 positive to exclude false positive detection. Further, we calculated the 165 percentage of galectin-3 positive cells and the average spots per cell. 166 Results 198
Drug sensitivity and resistance testing (DSRT) and high-content phenotypic drug profiling

Each tamoxifen-resistant cell line develops its individual gene expression and fusion gene profile 199
RNA-sequencing was performed to detect differentially expressed genes and pathways between parental 200 and resistant cell lines. Between 85 and 181 million filtered reads were obtained per sample (Additional 201
file 3), providing means to obtain expression estimates between 33,600 and 37,000 genes per sample. We 202 determined differential gene expression as log2 change of >|1|, and the difference of gene expression > 203 |10| CPM between the resistant clone and its isogenic parental cell line (see Methods). Using this filtering, 204 we identified >1200 differentially expressed genes in MCF-7-and T-47D-derived cells, and <400 genes in 205
BT-474-and ZR-75-1-derived cells. On average 59 % of differentially expressed genes were upregulated in 206 the majority of resistant cell lines (Table 1) . Interestingly, only about 35 % of altered genes in T-47D as 207 well as BT-474, and only 24 % in ZR-75-1 were shared between the resistant cells derived from the same 208 parental cell line and sampled at the same time point (Additional figure 1A) . Additionally, no common 209 differentially expressed genes were identified, highlighting that each of the resistant cell lines had 210 developed resistance through a distinct molecular pattern ( Figure 1A Interestingly, we found that patient-specific expression profiles clustered together with the expression of 222 the luminal A cells ( Figure 1D ). Furthermore, SERPINA1, which was differentially expressed in the 223 tamoxifen-resistant luminal A cell lines (being upregulated in MCF-7 Tam1 and downregulated in T-47D 224
Tam1, T-47D Tam2, ZR-75-1 Tam1 and ZR-75-1 Tam2), also changed its expression in the patient samples 225
(being up-regulated in all three metastatic tumors). CP (Ceruloplasmin), a gene that was highly 226 upregulated in the resistant T-47D cell lines (240-290 fold-increase) as well as MCF-7 Tam1 (26 fold-227 increase), was also found to be overexpressed in all the 3 metastatic patient samples ranging from 12-fold 228 increase (patient 2) to 50-57 fold increase (patient 1 and 3, respectively Additional file 5). 229
Triglyceride and cholesterol ester amounts are increased in the resistant T-47D cell lines 230
To reveal pathways associated with tamoxifen resistance, we analyzed the differentially expressed genes 231
with Enrichr (E. Y. Chen et al. 2013; Kuleshov et al. 2016 ). Based on the Reactome 2016 analysis, we 232 observed multiple enriched pathways in different resistant cell lines ( Table 2) . The most striking 233 differences were found in the T-47D Tam1 and Tam2 cells, which displayed changes in metabolism 234 associated genes, especially those involved in cholesterol and related lipid metabolism (Table 2, Figure  235 2A). 236
In addition, we observed an upregulation of genes involved in cholesterol biosynthesis, which was also 237 apparent in all metastatic patient samples from McBryan et al. study (Figure 2A ). Therefore, we focused 238 our studies on these pathways (Table 2) . To investigate whether deregulation of genes involved in 239 cholesterol biosynthesis could affect the cellular cholesterol balance, we stained cellular free cholesterol 240 with filipin, a fluorescent cholesterol-binding compound. Notably, we observed increased intracellular 241 amounts of free cholesterol in the resistant cells, displaying a cumulus cloud-like staining pattern ( Figure  242 2B). To quantify the presence of major cellular lipid species e.g. cholesterol, cholesterol esters, and 243 triglycerides, their amounts were further determined with thin layer chromatography. The total cellular 244 free cholesterol remained unchanged, suggesting that only the distribution of free cholesterol was altered 245
in the resistant cells. However, we observed an increase in neutral lipids (cholesterol esters and 246 triglycerides) upon tamoxifen treatment. The increase in triglycerides was strikingly high (4 to 7 fold-247 increase) in resistant cells compared to parental cells. To visualize the changes in neutral lipid amounts as 248 well as their intracellular distribution, we stained the cells with LipidToxGreen, a fluorescent dye binding 249 specifically to neutral lipids. The analysis indicated that most of the neutral lipids accumulated in enlarged 250 lipid droplets, which fill the cytoplasm ( Figure 2C & D) . Moreover, RNA sequencing results implicated that 251 the expression of Peroxisome Proliferator-Activated Receptor gamma (PPARG) was upregulated in 252 resistant cells. PPARG, which is normally expressed in a limited number of cells and regulates adipogenesis 253
as well as expression of several lipid droplet proteins (de la Rosa Rodriguez and Kersten 2017), was 254 upregulated in resistant cells. In addition, the ATP Binding Cassette Subfamily A Member 1 (ABCA1), which 255 functions as a cholesterol efflux pump was downregulated (Additional file 5). 256
Tamoxifen-resistant cells show altered morphology of lysosomes, have altered processing of Cathepsin 257 D, and are less susceptible to lysosomal membrane permeabilization 258
To localize the accumulated free cholesterol, we co-stained free cholesterol (filipin) with antibodies 259 detecting the lysosomal-associated-membrane-proteins 1 and 2 (Lamp1 and Lamp2). Based on this 260
analysis, we observed that most of the free cholesterol accumulated into lysosomes. We also discovered 261 an increase in the amount and size of lysosomes as well as divergences in shape compared to their typical 262 round form seen in the parental cell lines ( Figure 3A & B) . As the tamoxifen-resistant cells displayed a 263 prominent phenotype with free cholesterol accumulation to structurally disturbed lysosomes, we studied 264 the amounts of cathepsin D and its lysosomal maturation. Cathepsins are lysosomal proteins that help to 265 maintain the homeostasis of cell metabolism and are involved in apoptotic signaling as well as in lysosomal 266 membrane permeabilization. Furthermore, the expression of cathepsin D is known to be regulated by 267 estrogen (Rochefort et al. 1987 ). The amount of cathepsin D was decreased in tamoxifen-resistant cells. 268
As expected, we observed a decrease of mature cathepsin D (28 kDa) under tamoxifen treatment in 269 parental and resistant cell lines, suggesting that tamoxifen can regulate the expression and/or processing 270 of cathepsin D (Long and van den Berg 1996). Whilst addition of tamoxifen also caused an upregulation of 271 the precursors of cathepsin D in the parental cell line, such an increase was not obvious in the resistant 272 cell lines ( Figure 3E ), suggesting that the maturation of cathepsin D in the lysosomes may also be affected. 273
As lysosomal integrity, with cholesterol content of lysosomal membranes and cathepsin D among its 274 regulators, plays an important role in the induction of cell death (Galluzzi, Bravo-San Pedro, and Kroemer 275 2014), we monitored the translocation of galectin-3 to detect LMP. Given that galectin-3 translocation to 276 the lysosomes was not detected in the parental cells when grown without tamoxifen, and that only very 277 few tamoxifen-treated cells showed galectin-3 spots ( Figure 3C & D) , lysosomes were most likely 278 undamaged and functional in all cells. Further, by inducing LMP with 1 mM LLOMe we were able to 279 observe that tamoxifen treated resistant cells were less susceptible to LMP compared to the parental cell 280 line, having only 51-53% of cells with galectin-3 spots under tamoxifen treatment and less galectin-3 spots 281 per cell ( Figure 3C & D) . This suggests that circumvention of LMP in the resistant cells leads not only to 282 tamoxifen resistance but may also decrease their sensitivity to other drugs. 283
Drug testing of tamoxifen resistant cells reveals sensitivity to dasatinib, disulfiram and LCS-1 284
Guided by our RNA-sequencing results we selected 33 drugs, known to affect the genes or pathways 285 involved in lysosomal alterations and lipid metabolism as well as some drugs identified in our previous 286 screen (Additional file 2, Kangaspeska et al. 2016 ). As readouts for the DSRT, we applied both enzymatic 287 cell viability measurement (CTG) as well as a phenotypic image-based analysis using LipidToxGreen to 288 observe neutral lipids in lipid droplets together with Hoechst to detect nuclei. 289
The cell viability measurement revealed drugs that reduced ATP levels in tamoxifen-resistant cells similarly 290 to the control cells, independently of their lipid accumulation phenotype (Figure 4A , Additional file 6). 291
Dasatinib, a dual Abl/Src inhibitor was more effective in killing the tamoxifen resistant cell lines compared 292
with the parental cells in agreement with our previous results (Kangaspeska et al. 2016) . Tamoxifen-293 resistant cells were more sensitive to microtubule depolymerizing drugs, such as vincristine and 294 vinorelbine, when measured by ATP amounts. Interestingly, the T-47D Tam2 cells were especially sensitive 295
to vinorelbine induced cytotoxicity ( Figure 4A , Additional file 6). The mitotic inhibitors paclitaxel and 296 docetaxel (microtubule stabilizers) were less effective in the T-47D Tam1 cells. (Figure 4A , Additional file 297 6). 298
The most effective drug against all the T-47D clones was disulfiram, a specific inhibitor of aldehyde-299 dehydrogenase (ALDH1). All the clones responded to AZD8055, a dual mTOR inhibitor, although T-47D 300
Tam1 and Tam2 showed reduced sensitivity. Atorvastatin, which inhibits HMGCoA reductase, did not 301 affect the CTG DSS levels ( Figure 4A ) but was able to reduce the cell count in the parental and even more 302 in the T-47D Tam2 cells ( Figure 4B) . The SOD-1 inhibitor LCS-1 was effectively killing both parental and 303
resistant T-47D clones, and RSL-3, a ferroptosis activator due to inhibition of glutathione peroxidase 4, 304
induced cell death in all the cell lines, with somewhat reduced response in T-47D Tam1 (Figure 4B,  305 Additional file 6). 306
To see whether any of the compounds are able to revert the lipid phenotype prior to reducing the cell 307 viability (ATP-measurement) or induction of cell death (cell count), we specifically monitored the changes 308 in neutral lipids by measuring the mean signal of LipidToxGreen in each cell. We then calculated the mean 309 of these single-cell measurements to quantify the average LipidToxGreen intensity per well. The measured 310 increase in the intensity was within the 2-fold range, and we were able to confirm the trends from the 311 biochemical screen where we observed a neutral lipid accumulation in the resistant cell lines ( Figure 2C , 312 Figure 4C ). Whereas most of the drugs had minor effects on the LipidToxGreen intensity (Additional file 313 7), the LXR-agonist TO901317 increased the lipid phenotype most strikingly in the parental cells, with less 314 increase particularly in T-47D Tam1 cells ( Figure 4D ). In addition, methyl-b-cyclodextrin, a membrane 315 cholesterol-depleting agent, caused a lipid droplet accumulation phenotype, mostly in the parental cell 316 line prior to cell killing in the highest concentration (Additional file7). 317 318
Discussion 319
In this study, we utilized RNA-sequencing and pathway analysis to understand the underlying tamoxifen 320 resistance and identify resistance-specific drug vulnerabilities. We revealed the involvement of lipid 321 metabolism in tamoxifen resistance as well as pointed out potential therapeutic ways to target these 322 pathways. 323
Gene expression analysis on tamoxifen-resistant cells reinforced our previous finding on breast cancer 324 cells using a variety of molecular pathways as they acquire tamoxifen resistance (Kangaspeska et al. 2016 ). 325
The difference in gene expression was reflected in the scale and scope of differentially expressed genes, 326
and in the lack of shared genes across all the cell lines. However, a few genes were concordantly 327 differentially expressed between the luminal A subtype (Figure 1, Additional figure 1 ). In agreement with 328 this finding, the only study that has performed sequential tumor transcriptome analysis on patients 329
developing endocrine resistance, also identified less than 3% of differentially expressed genes across able to identify five genes that were concordantly differentially expressed in the luminal A subtype 333 resistant cells (Additional figure 1B) . Of these, SERPINA1, encoding for a serine protease inhibitor primarily 334 targeting elastase, is known to bind ER in a 17β-estradiol (E2) -independent manner, which leads to an 335 increase in its expression (Chan et al. 2015) . In our resistant lines, SERPINA1 expression increased in MCF-336 7 Tam1 and decreased in the resistant clones of T-47D and ZR-75-1 (Additional file 5). This could be due 337 to the down-and upregulation of ER in these cell lines (Kangaspeska et al. 2016) . Interestingly, in all three 338 metastatic samples from the McBryan et al. study, we observed an increase in SERPINA1, which is 339 accompanied by a slight increase of ESR1 transcription (Additional file 5). Pathway analysis of the 340 differentially expressed genes identified several paths involved in acquired tamoxifen resistance (Table 2 , 341 Figure 2A ). 342
In this study, we investigated the tamoxifen-induced changes observed in lipid metabolism (Table 2, Figure  343 2). In addition to detecting an increase in expression of genes linked to cholesterol biosynthesis in the 344 resistant cell lines, we also made the equivalent finding in a patient's metastatic tissue (Figure 2A ). As the 345 metastasis was found in the liver (McBryan et al. 2015) , the observed lipid metabolism pathway profiles 346
have to be interpreted with caution. Nevertheless, our findings suggest that the lipid phenotypes could 347 already develop in the breast cancer cells (Luo et al. 2017 ) and is not solely induced by the liver 348 environment. Further, our studies with the T-47D tamoxifen-resistant cell lines show an increase of free 349 cholesterol in lysosomes ( Figure 2B , Figure 3A & B, Suárez et al. 2004 ). Additionally, we observed an 350 increase in cholesterol esters ( Figure 2C ), suggesting that the tamoxifen-resistant cells can convert the 351 excess cholesterol to cholesterol ester storage. We also observed a striking enlargement of the lysosomal 352 compartment. As lysosomes and lysosomal proteins have recently been recognized to play a key role in 353 the resistance to a wide spectrum of commonly used anticancer drugs (Hämälistö and Jäättelä 2016), our 354 findings suggest that excess tamoxifen could be stored in these enlarged lysosomes, and its sequestration 355 could contribute to the resistance of the cells to tamoxifen. Lamp2, as well as a decrease in cathepsin D (Long and van den Berg 1996, Figure 2B , Figure 3A , B and E).
363
A short-term tamoxifen treatment diminished directly the LLOMe-induced LMP, measured by the 364 recruitment of galectin-3 into lysosomes. The T-47D Tam1 and Tam2 were even more resistant towards 365 LMP ( Figure 3C and D) , showing that tamoxifen can hinder it, and in acquired resistance, this phenomenon 366 is even more prominent. Thus, impeded lysosomal membrane permeabilization may additionally enhance 367 the co-resistance to other cancer drugs during acquired tamoxifen resistance. 368
An enormous increase in triglycerides, stored in large lipid droplets (LDs) was observed in tamoxifen-369 resistant cells. Free fatty acids are enzymatically converted to triacylglycerol, and then incorporated into 370
LDs. Packaging of excess lipids into LDs could be seen as an adaptive response to fulfilling energy supply 371 without hindering mitochondrial or cellular redox status and keeping the concentration of lipotoxic 372
intermediates low (Aon, Bhatt, and Cortassa 2014). Accordingly, high LDs and stored cholesterol esters in 373 tumors are considered as hallmarks of aggressive cancer (Beloribi-Djefaflia, Vasseur, and Guillaumond 374 2016). LD-rich cancer cells have also been shown to be more resistant to chemotherapy (Qiu et al. 2015) . 375 We found over 3-fold upregulation of stearoyl-CoA desaturase (SCD), encoding for a rate-limiting enzyme 376
in the biosynthesis of monounsaturated fatty acids, in the tamoxifen-resistant T-47Ds (Additional file 5). 377
Whether it alone is able to induce the increase in TGs, remains to be investigated. In line with this 378 speculation, SCD overexpression has been observed, in different cell types as well as in tamoxifen-induced 379 hepatocyte steatosis, to significantly increase the rate of triglyceride synthesis (Zhao et al. 2014) . 380
We also investigated the effects of 33 compounds that were selected to influence the lysosomal integrity 381 and act on lipid metabolism (Additional file 2). The compounds directly affecting lipid metabolism, such 382 as C75, Bezafibrate, T 0070907, TO901317, and Orlistat, had no or only little effect on cell viability or the 383 lipid phenotype (Figure 4 and Additional files 6, 7).This suggests that the T-47D cells are able to 384 compensate the drug-induced lipid imbalance with several mechanisms. We observed that AZD8055, a 385 drug that has been shown to reduce cellular de novo lipid synthesis in breast cancer cells (Qian et al. 2016) 386 was less effective in the tamoxifen-resistant cells than in parental cells (Additional file 6), which could 387
indicate that de novo lipid synthesis might not solely be responsible for the neutral lipid accumulation. 388
Surprisingly, methyl-b-cyclodextrin caused an increase in neutral lipid accumulation prior to the cell death 389 mainly in the parental T-47Ds as well as to a minor extant in the resistant cell lines (Additional file7). 390
Methyl-b-cyclodextrin has been shown to sensitize cells towards tamoxifen-mediated cell death (Tiwary 391 et al. 2011; Mohammad et al. 2014) . 392
Disulfiram, which targets ALDH1 to increase oxidative stress, was highly effective in both parental and 393
tamoxifen-resistant T-47D cell clones (Figure 4 and Additional file 6). The effectiveness of disulfiram is 394 currently investigated in metastatic breast cancer in a phase II clinical trial (ClinicalTrials.gov, 395 NCT03323346). ALDH2, another target of disulfiram, is upregulated in T-47D Tam1 but not in Tam2 396
(Additional file 5). High levels of ALDH1 have been shown to predict resistance in women treated with 397 tamoxifen (Simões et al. 2015) , but as ALDH1A1 is expressed at very low levels in the T-47D cell lines 398
(Additional file 5), we assume that the sensitivity to disulfiram could be due to its capability to disable 399 antioxidation mechanisms of the cells (Hangauer et al. 2017 ). Further, as the effects of disulfiram are 400 usually boosted by copper, and we additionally saw an increase in expression of the copper-binding 401 enzyme ceruloplasmin, one would assume that disulfiram would be more effective in the tamoxifen-402 resistant cell lines. 403
Reducing the reactive oxygen species (ROS) is another mechanism by which cells avoid lysosomal induced 404 cell death (Aits and Jäättelä 2013). We speculate that resistant T-47D cells are able to reduce oxidative 405 stress by upregulation of SOD1 (Additional file 5) and may therefore be less sensitive to lysosomal cell 406 death. This hypothesis is further supported by the fact that the resistant cells were highly sensitive to the 407 SOD1 inhibitor LCS-1. The capability of erastin to activate ferroptosis is instead inhibited by antioxidants, 408
and it was more effective in parental than in resistant cells. The ferroptosis activator RSL-3, which inhibits 409 the glutathione peroxidase 4, an enzyme that protects from oxygen damage, induced cell death in all the 410 cell lines (Figure 4 and Additional file 6). This further supports the assumption that the T-47D cells are able 411 to reduce oxidative stress and are therefore less sensitive to lysosomal cell death. 412 413
Taken together, our results highlight that tamoxifen resistant cell lines can potentially be used as a 414
representative model for studies of tamoxifen-resistant patients. We propose that the breast cancer cells 415 can acquire tamoxifen resistance by dysregulation of different cellular pathways, dependent on their 416 individual molecular phenotypes. Here, we highlight the inhibition of lysosomal membrane 417 permeabilization as one of the mechanisms to avoid cell death, whereas an increase in neutral lipids may 418 enable the further survival of these cells. We further propose that drugs targeting cellular antioxidation 419 machinery may be able to overcome tamoxifen resistance. Given the vulnerability of tamoxifen resistant 420 cells to approved drugs such as disulfiram and dasatinib, it would be interesting to investigate whether 421 these compounds could also be effective in clinical trials in tamoxifen-resistant breast cancer patients. 422
We 
